News

Israel-based XTL Biopharmaceuticals, a clinical stage biotech company that focuses on the development of new drugs for the treatment of autoimmune diseases, has announced that its lead drug candidate, hCDR1, has been granted a patent by the Hungarian Intellectual Property Office. The patent, “Synthetic Human Peptides and Pharmaceutical Compositions Comprising…

Aurinia Pharmaceuticals recently announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to voclosporin, a next-generation calcineurin inhibitor under development to treat patients with lupus nephritis (LN) and other autoimmune diseases. LN is a kidney inflammation caused by systemic lupus erythematosus (SLE) in which patients may develop proteinuria,…

Researchers from Singapore’s leading science institute, A*STAR, found that a group of small noncoding RNAs, called mir-17-92, regulate B-cell function and antibodies in mice. The results may help pave the way for new lupus treatments and other diseases linked to B-cell dysfunction. Antibody-producing B-cells are a crucial part of our defense against pathogens. In autoimmune…

Immunovia AB recently announced it has entered into a collaboration with a large multinational life science company to jointly conduct trials to expand the application of IMMray, a technology platform based on antibody microarray analysis, to include autoimmune diseases like systemic lupus erythematosus (SLE). The company was not otherwise…

A collaborative research project conducted between The Scripps Research Institute in La Jolla, California; Yale University  in New Haven, Connecticut; and National Biotechnology Center in Madrid, Spain, has identified a small molecule called miR-148a as a key regulator of immune cells, where higher levels appear to cause autoimmune diseases. The paper, “…